M Joglekar1, S Khandelwal1, D B Cines2, M Poncz3, L Rauova3, G M Arepally1. 1. Division of Hematology, Duke University Medical Center, Durham, NC, USA. 2. Department of Pathology and Laboratory Medicine, Perelman-University of Pennsylvania School of Medicine, Philadelphia, PA, USA. 3. Division of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Abstract
BACKGROUND: Heparin-induced thrombocytopenia (HIT) is an iatrogenic complication of heparin therapy caused by antibodies to a self-antigen, platelet factor (4) and heparin. The reasons why antibodies form to PF4/heparin, but not to PF4 bound to other cellular glycosaminoglycans are poorly understood. OBJECTIVE: To investigate differences in cellular responses to cell-bound PF4 and PF4/heparin complexes, we studied the internalization of each by peripheral blood-derived monocytes, dendritic cells and neutrophils. METHODS AND RESULTS: Using unlabeled and fluorescently-labeled antigen and/or labeled monoclonal antibody to PF4/heparin complexes (KKO), we show that PF4/heparin complexes are taken up by monocytes in a heparin-dependent manner and are internalized by human monocytes and dendritic cells, but not by neutrophils. Complexes of PF4/low-molecular-weight heparin and complexes composed of heparin and murine PF4, protamine or lysozyme are internalized similarly, suggesting a common endocytic pathway. Uptake of complexes is mediated by macropinocytosis, as shown by inhibition using cytochalasin D and amiloride. Internalized complexes are transported intact to late endosomes, as indicated by co-staining of vesicles with KKO and lysosomal associated membrane protein-2 (LAMP-2). Lastly, we show that cellular uptake is accompanied by expression of MHCII and CD83 co-stimulatory molecules. CONCLUSIONS: Taken together, these studies establish a distinct role for heparin in enhancing antigen uptake and activation of the initial steps in the cellular immune response to PF4-containing complexes.
BACKGROUND:Heparin-induced thrombocytopenia (HIT) is an iatrogenic complication of heparin therapy caused by antibodies to a self-antigen, platelet factor (4) and heparin. The reasons why antibodies form to PF4/heparin, but not to PF4 bound to other cellular glycosaminoglycans are poorly understood. OBJECTIVE: To investigate differences in cellular responses to cell-bound PF4 and PF4/heparin complexes, we studied the internalization of each by peripheral blood-derived monocytes, dendritic cells and neutrophils. METHODS AND RESULTS: Using unlabeled and fluorescently-labeled antigen and/or labeled monoclonal antibody to PF4/heparin complexes (KKO), we show that PF4/heparin complexes are taken up by monocytes in a heparin-dependent manner and are internalized by human monocytes and dendritic cells, but not by neutrophils. Complexes of PF4/low-molecular-weight heparin and complexes composed of heparin and murinePF4, protamine or lysozyme are internalized similarly, suggesting a common endocytic pathway. Uptake of complexes is mediated by macropinocytosis, as shown by inhibition using cytochalasin D and amiloride. Internalized complexes are transported intact to late endosomes, as indicated by co-staining of vesicles with KKO and lysosomal associated membrane protein-2 (LAMP-2). Lastly, we show that cellular uptake is accompanied by expression of MHCII and CD83 co-stimulatory molecules. CONCLUSIONS: Taken together, these studies establish a distinct role for heparin in enhancing antigen uptake and activation of the initial steps in the cellular immune response to PF4-containing complexes.
Authors: Marie-Luce De Temmerman; Joanna Rejman; Jo Demeester; Darrell J Irvine; Bruno Gander; Stefaan C De Smedt Journal: Drug Discov Today Date: 2011-05-04 Impact factor: 7.851
Authors: G M Arepally; S Kamei; K S Park; K Kamei; Z Q Li; W Liu; D L Siegel; W Kisiel; D B Cines; M Poncz Journal: Blood Date: 2000-03-01 Impact factor: 22.113
Authors: L Thiele; B Rothen-Rutishauser; S Jilek; H Wunderli-Allenspach; H P Merkle; E Walter Journal: J Control Release Date: 2001-09-11 Impact factor: 9.776
Authors: Jurjen Tel; Annechien J A Lambeck; Luis J Cruz; Paul J Tacken; I Jolanda M de Vries; Carl G Figdor Journal: J Immunol Date: 2010-03-19 Impact factor: 5.422
Authors: Tamam Bakchoul; Heike Zöllner; Jean Amiral; Simon Panzer; Sixten Selleng; Thomas Kohlmann; Sven Brandt; Mihaela Delcea; Theodore E Warkentin; Ulrich J Sachs; Andreas Greinacher Journal: Blood Date: 2013-01-16 Impact factor: 22.113
Authors: Lubica Rauova; Mortimer Poncz; Steven E McKenzie; Michael P Reilly; Gowthami Arepally; John W Weisel; Chandrasekaran Nagaswami; Douglas B Cines; Bruce S Sachais Journal: Blood Date: 2004-08-10 Impact factor: 22.113
Authors: Sufeng Zhang; Won Joon Cho; Amy T Jin; Lie Yun Kok; Yunhua Shi; David E Heller; Young-Ah Lucy Lee; Yixuan Zhou; Xi Xie; Joshua R Korzenik; Jochen K Lennerz; Giovanni Traverso Journal: Adv Healthc Mater Date: 2020-06-29 Impact factor: 9.933
Authors: Sanjay Khandelwal; Grace M Lee; C Garren Hester; Mortimer Poncz; Steven E McKenzie; Bruce S Sachais; Lubica Rauova; Garnett Kelsoe; Douglas B Cines; Michael Frank; Gowthami M Arepally Journal: Blood Date: 2016-07-13 Impact factor: 22.113
Authors: Douglas B Cines; Serge V Yarovoi; Sergei V Zaitsev; Tatiana Lebedeva; Lubica Rauova; Mortimer Poncz; Gowthami M Arepally; Sanjay Khandelwal; Victoria Stepanova; Ann H Rux; Adam Cuker; Cecilia Guo; Linnette Mae Ocariza; Richard J Travers; Stephanie A Smith; Hugh Kim; James H Morrissey; Edward M Conway Journal: Blood Adv Date: 2016-11-22